CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2017 State of the Science Summit on Melanoma and Immuno-Oncology
Oncology Conference Multimedia
View more videos >>
Dr. Stein on Targeted Therapies for Melanoma
Dr. Meehan on Importance of IHC Testing in Melanoma
Dr. Berman on Evolving Role of Surgery in Melanoma
Oncology Conference Articles
Amid Molecular Diagnostic Advances, IHC Retains Significance in Melanoma
Shane A. Meehan, MD, discusses the continued importance of IHC testing in melanoma, even with the emergence of novel molecular assays.
Expert Shares Optimism on Surgical Advances in Melanoma
Russell Berman, MD, discusses ongoing surgical advances in the treatment of melanoma.
Surgical and Systemic Techniques Evolving for Melanoma Patients With Brain Mets
Douglas Kondziolka, MD, provides insight on some of the technical advancements in treating brain metastases in patients with melanoma.
Dermatologic Management of Melanoma Involves Observation of Skin AEs and New Primary Melanomas
Jennifer A. Stein, MD, PhD, discusses the skin-related adverse events for patients on treatment for melanoma, as well as the importance of identifying new primary melanomas.
Clinical Trials Are Essential in the Adjuvant Setting for High-Risk Melanoma
Anna C. Pavlick, DO, discusses adjuvant therapy for patients with high-risk melanoma.
Weber Says Pembrolizumab/Epacadostat Could Become Frontline Treatment of Choice in Melanoma
Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).
Expert Highlights Impressive Long-Term Activity With BRAF/MEK Combos in Melanoma
Melissa A. Wilson, MD, PhD, discussed the promising results with BRAF/MEK inhibitor combinations in melanoma and what ongoing studies have the potential to alter the landscape again.
Burden of Cardiovascular Disease in Prostate Cancer
The Role of Patient Education in Side Effect Management
Will Precision Medicine Displace the Randomized Trial?
Sorting Through the Alphabet Soup of Evolving Treatments in CLL
FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.